logo

FX.co ★ Sartorius Stedim Biotech Preliminary FY24 Profit Declines - Quick Facts

Sartorius Stedim Biotech Preliminary FY24 Profit Declines - Quick Facts

Sartorius Stedim Biotech has disclosed its preliminary financial results for the fiscal year 2024, revealing a net profit of €175.1 million, which signifies a 43.6% decrease compared to the previous year. The earnings per share declined to €1.81 from €3.37. The underlying EBITDA reported a slight decrease of 0.8%, amounting to €779 million, while underlying earnings per share dropped to €3.49 from €4.19.

In terms of sales revenue for 2024, the company reported €2.78 billion, representing a modest increase of 0.2% in reported figures, a 0.6% rise when adjusted for constant currencies, and a 0.7% decline on an organic basis in constant currencies. The order intake witnessed a robust growth, increasing by 12.9% in constant currencies and 12.3% in reported terms.

During the fourth quarter, sales revenue reached €751 million, marking a 6.1% increase in constant currencies and a 6.3% rise in reported figures. The order intake for this period saw a significant surge of 23.8% in constant currencies.

यह भी देखें: आप यहां एक ट्रेडिंग खाता खोल सकते हैं

Looking ahead to 2025, the management anticipates achieving profitable, moderate growth surpassing the market average. The company aims to continue profitable growth beyond the market level and expects a moderate increase in sales revenue. Additionally, it projects that the underlying EBITDA will grow at a rate exceeding that of sales revenue.

*यहाँ दिया गया बाजार का विश्लेषण आपकी जागरूकता को बढ़ाने के लिए है, यह ट्रेड करने का निर्देश नहीं है
लेख सूची पर जाएं ट्रेडिंग खाता खोलें